Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurobindo PharmaBOM:524804 -0.11%85 Days Payable is 148.15 as of Mar. 2026, which is 38% above its 10-year median of 107.66. GuruFocus rates BOM:524804 with a GF Score™ of 85/100 and a GF Value™ of ₹1,337.25 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 927 Drug Manufacturers companies, Aurobindo Pharma ranks better than 69.69% on this metric.
The historical rank and industry rank for Aurobindo Pharma's Days Payable or its related term are showing as below:
BOM:524804'
s Days Payable Range Over the Past 10 Years
Min: 90.75 Med: 107.66 Max: 132
Current: 130.85
During the past 13 years, Aurobindo Pharma's highest Days Payable was 132.00. The lowest was 90.75. And the median was 107.66.
BOM:524804's Days Payable is ranked better than 69.69% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:524804: 130.85
Aurobindo Pharma's Days Payable
increased
from Mar. 2025 (111.51) to Mar. 2026 (148.15).
It may suggest that Aurobindo Pharmadelayed paying its suppliers.
Aurobindo Pharma Days Payable Related Terms
Aurobindo Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Aurobindo Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurobindo Pharma Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Aurobindo Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aurobindo Pharma's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurobindo Pharma (BOM:524804) has a Days Payable of 148.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurobindo Pharma and its competitors. This is 38% above median its historical median of 107.66. Over the past decade, Aurobindo Pharma's Days Payable has ranged from 90.75 to 132.00. According to the industry distribution chart, Aurobindo Pharma ranks #281 out of 927 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Aurobindo Pharma's Days Payable too high?
Aurobindo Pharma's current Days Payable of 148.15 is 38% above median its 10-year median of 107.66. Over the past 10 years, this metric has ranged from a low of 90.75 to a high of 132.00. The Drug Manufacturers industry median Days Payable is 90.38. Aurobindo Pharma's value of 148.15 is 63.9% above this industry median. Based on the distribution chart, Aurobindo Pharma ranks #281 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurobindo Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurobindo Pharma ranks #281 out of 927 companies for Days Payable. This puts Aurobindo Pharma in the upper half of its industry. The industry median Days Payable is 90.38. Aurobindo Pharma's value of 148.15 is 63.9% above this benchmark. Historically, Aurobindo Pharma's own Days Payable has ranged from 90.75 to 132.00 over the past decade. While the company's 10-year median is 107.66 vs. the industry median of 90.38, Aurobindo Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurobindo Pharma's current Days Payable of 148.15 is 63.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aurobindo Pharma and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurobindo Pharma's current Days Payable is 148.15, which is 38% above median its own 10-year median of 107.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,337.25, compared to a current price of ₹1,551.15 — trading 16% above its estimated fair value. The current Days Payable is 148.15, which is 38% above median its 10-year median of 107.66 and 63.9% above the Drug Manufacturers industry median of 90.38. Aurobindo Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current Days Payable is 148.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?
Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued.
The current stock price of ₹1,551.15 is trading 16% above its estimated GF Value™ of ₹1,337.25.
GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.
Key valuation signals for BOM:524804:
Days Payable: 148.15 (38% above median its 10-year median of 107.66)
GF Value™: ₹1,337.25 vs. price of ₹1,551.15 (16% above fair value)
Industry Position: 63.9% above the Drug Manufacturers median (#281 of 927)
No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
85GF Score
Get the complete analysis for BOM:524804
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524804 has been successfully added to your 
